Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et 24-ugers prospektivt, åbent, multicenter, enkeltarms rPMS-studie i den virkelige verden for Atectura®

21. september 2026 opdateret af: Novartis Pharmaceuticals

Et 24-ugers prospektivt, åbent, multicenter, enkeltarms regulatorisk post-markedsføringsovervågning (rPMS) undersøgelse i virkelige omgivelser (obligatorisk af lokal HA-regulering) for Alectura® (QMF149 150/80 μg o.d., QMF149 150/ 160 μg o.d. og QMF149 150/320 μg o.d. Via Breezhaler)

This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Atectura inhalation capsule for up to 24 weeks under routine clinical practice.

Studieoversigt

Detaljeret beskrivelse

The three different doses of Atectura inhalation capsule via Breezhaler will be prescribed according to the approved label information in Korea, and the investigation for any additional diagnostic or monitoring will be not conducted for this study

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

670

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Busan, Sydkorea, 48108
        • Novartis Investigative Site
      • Gyeongsangnam Do, Sydkorea, 51353
        • Novartis Investigative Site
      • Jeju City, Sydkorea, 63241
        • Novartis Investigative Site
      • Seoul, Sydkorea, 05505
        • Novartis Investigative Site
      • Seoul, Sydkorea, 04763
        • Novartis Investigative Site
      • Seoul, Sydkorea, 06273
        • Novartis Investigative Site
      • Seoul, Sydkorea, 137 707
        • Novartis Investigative Site
      • Taegu, Sydkorea, 41944
        • Novartis Investigative Site
      • Ulsan, Sydkorea, 44033
        • Novartis Investigative Site
    • Dalseo gu
      • Daegu, Dalseo gu, Sydkorea, 42602
        • Novartis Investigative Site
    • Gangneung si
      • Kangwon Do, Gangneung si, Sydkorea, 210 711
        • Novartis Investigative Site
    • Gangwon-do
      • Wŏnju, Gangwon-do, Sydkorea, 26426
        • Novartis Investigative Site
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Sydkorea, 10380
        • Novartis Investigative Site
      • Guri-si, Gyeonggi-do, Sydkorea, 11923
        • Novartis Investigative Site
    • Gyeongsangnam-do
      • Jinju, Gyeongsangnam-do, Sydkorea, 52727
        • Novartis Investigative Site
    • Jeollabuk-do
      • Jeonju, Jeollabuk-do, Sydkorea, 54907
        • Novartis Investigative Site
    • Jeonlabuk Do
      • Iksan Si, Jeonlabuk Do, Sydkorea, 54538
        • Novartis Investigative Site
    • Korea
      • Daejeon, Korea, Sydkorea, 35015
        • Novartis Investigative Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år til 100 år (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

subjects who received at least one dose of Atectura inhalation capsule via Breezhaler and that have provided consent for their data collection.

Beskrivelse

Inclusion Criteria:

  1. Adolescent (≥12 years of age) and adult patients with a physician's diagnosis of asthma, who are prescribed Atectura inhalation capsule (indacaterol acetate/mometasone furoate; 150/80, 150/160, 150/320 μg) via Breezhaler, as per the approved label information
  2. Patients who participate in the study after signing the consent form for data collection and use (Data Privacy ICF) after receiving a clear explanation of the objectives and nature of the study from the investigator (For patients under the age of 18, consent and signature of a legal representative is required)

Exclusion Criteria:

  1. Patients who are contraindicated for this medicinal product as described in the Precautions for Use in the label information (package insert) A. Patients with hypersensitivity reaction to this medicinal product or any of its constituents B. Because this medicinal product contains lactose, patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc.
  2. Patients with acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required
  3. Patients participating in other interventional clinical trials

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Atectura inhalation capsule (150/80ug)

Indacaterol acetate/Mometasone furoate; 150/80ug

There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.

Atectura inhalation capsule (150/160ug)

Indacaterol acetate/Mometasone furoate; 150/160ug

There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.

Atectura inhalation capsule (150/320ug)

Indacaterol acetate/Mometasone furoate; 150/320ug

There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of adverse events and serious adverse events
Tidsramme: 24 weeks

Incidence of AE and SAE will be collected

24 weeks
Incidence of unexpected adverse events and unexpected serious adverse events
Tidsramme: 24 weeks

Incidence of unexpected AE and SAE will be collected. The term "unexpected" means not listed in local label

24 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
change from baseline in trough FEV1
Tidsramme: Baseline, week 12

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.

Baseline, week 12
change from baseline in ACT score
Tidsramme: Baseline, week 12

The Asthma Control Test (ACT) is a validated tool to assess overall asthma control. It is a 1 page questionnaire consisting of 5 simple questions assessing: asthma symptoms, use of rescue medications, and the impact of asthma on everyday functioning. All questions are scored on a 5-point Likert scale, with a higher score indicating better control. All scores are added together to calculate a total score. Total score ranges from 5 to 25. A positive change indicates improvement.

Baseline, week 12
Effective rate and ineffective rate by investigator assessment
Tidsramme: week 12

Effective (improved) rate and ineffective (unchanged/aggravated) rate by investigator assessment

week 12
Baseline characteristics of patients showing adverse events/adverse drug reactions
Tidsramme: 24 weeks

The incidence rates of AEs/ADRs will be presented by factors, such as subject baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations.

24 weeks
Baseline characteristics of patient in relation to changes from baseline through FEV1 and ACT score
Tidsramme: 12 weeks

Regression analysis will be performed to determine factors affecting the change in trough FEV1 and ACT score, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations

12 weeks
Baseline characteristics of patients in relation to the investigator assessment
Tidsramme: 12 weeks

Logistic regression analysis will be performed to determine factors affecting the effectiveness (improved) in the investigator assessment, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations.

12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

9. maj 2022

Primær færdiggørelse (Anslået)

24. december 2026

Studieafslutning (Anslået)

24. december 2026

Datoer for studieregistrering

Først indsendt

30. november 2021

Først indsendt, der opfyldte QC-kriterier

19. januar 2022

Først opslået (Faktiske)

1. februar 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

21. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner